Concepedia

Laure Montané

LM

6

Publications

327

Citations

6

H-Index

2018

Active since

Affiliations

Centre Léon Bérard(Current)

Université Claude Bernard Lyon 1

Inserm

Université Grenoble Alpes

Centre Hospitalier Universitaire de Grenoble

Laure Montané is an author at Centre Léon Bérard specializing in medicine, molecular oncology, and cancer therapeutics.

Top concepts

Publications per year

2018–2024

6

Publications

6

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

Julien Mazières, Claire Cropet, Laure Montané et al. · Annals of Oncology · 2020 · 185 citations

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

Philippe A. Cassier, Gwenaëlle Garin, Lauriane Eberst et al. · Journal of Clinical Oncology · 2019 · 45 citations

, , +21

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers

Aurélien Voissière, Carlos Gomez‐Roca, Sylvie Chabaud et al. · Science Translational Medicine · 2024 · 41 citations

MEVITEM—a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation

Didier Frappaz, Marc Barritault, Laure Montané et al. · Neuro-Oncology · 2021 · 32 citations · Full text

LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial

A. González Martín, Youssef Tazi, Florian Heitz et al. · Annals of Oncology · 2020 · 13 citations · Full text

, , +9

Rows per page

1–5 of 6